Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 5.38 GBp
Change Today 0.00 / 0.00%
Volume 635.7K
As of 11:35 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

reneuron group plc (RENE) Snapshot

Open
5.38 GBp
Previous Close
5.38 GBp
Day High
5.38 GBp
Day Low
5.38 GBp
52 Week High
06/10/15 - 6.38 GBp
52 Week Low
01/22/15 - 3.00 GBp
Market Cap
169.6M
Average Volume 10 Days
2.1M
EPS TTM
-0.0046 GBp
Shares Outstanding
3.2B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RENEURON GROUP PLC (RENE)

Related News

No related news articles were found.

reneuron group plc (RENE) Related Businessweek News

No Related Businessweek News Found

reneuron group plc (RENE) Details

ReNeuron Group plc engages in the clinical-stage cell therapy development business worldwide. Its lead therapeutic candidate is CTX stem cell therapy, which is in Phase II clinical trial for the treatment of patients left disabled by the effects of a stroke. The company is also developing CTX stem cell candidate that is in Phase I dose escalation clinical trial for the treatment of critical limb ischaemia, a side effect of diabetes; and human retinal progenitor cell stem cell candidate for the treatment of retinitis pigmentosa, a blindnesscausing disease of the retina. In addition, it develops CTX-derived exosomes, which are nanoparticles released by cells containing active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

33 Employees
Last Reported Date: 08/24/15
Founded in 1997

reneuron group plc (RENE) Top Compensated Officers

Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: 228.0K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 262.0K GBP
Compensation as of Fiscal Year 2014.

reneuron group plc (RENE) Key Developments

ReNeuron Group plc Reports Unaudited Earnings Results for the Year Ended March 31, 2015

ReNeuron Group plc reported unaudited earnings results for the year ended March 31, 2015. For the year, the company reported royalty income of GBP 30,000 against GBP 22,000 a year ago. Operating loss was GBP 10,394,000 against GBP 7,969,000 a year ago. Loss before income taxes was GBP 10,303,000 against GBP 7,820,000 a year ago. Total comprehensive loss attributable to equity owners of the company was GBP 8,906,000 against GBP 7,066,000 a year ago. Basic and diluted loss per share was 0.5 pence against 0.5 pence a year ago. Cash used in operating activities was GBP 8,245,000 against GBP 6,004,000 a year ago, largely reflecting the operating costs incurred during the period, less tax credits received. Capital expenditure was GBP 380,000 against GBP 121,000 a year ago.

ReNeuron Group plc, 2015 Earnings Call, Jul 10, 2015

ReNeuron Group plc, 2015 Earnings Call, Jul 10, 2015

ReNeuron Group plc Announces Management Appointments

ReNeuron Group plc announced two further senior management appointments. Dr. Julian Howell will be joining the company as Chief Medical Officer, with responsibility for clinical development activities at the Company. Dr. Howell has held a number of leadership roles in clinical development during the last 15 years, bringing small molecules and biological products through all phases of clinical development in Europe and the US. He joins ReNeuron from Shield Therapeutics, where he held the role of Group Medical Director. Shaun Stapleton has been appointed as Head of Regulatory Affairs at the company. Mr. Stapleton joins ReNeuron from RRG (a Voisin Consulting Life Sciences Company) where he was a Director and Vice President of Regulatory Science. He supported clients on a number of global development and registration projects, including advanced therapies and orphan drugs. Having graduated in Biochemistry from Imperial College, London, Mr. Stapleton began his career in research with the Imperial Cancer Research Fund, before moving into the pharmaceutical industry.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RENE:LN 5.38 GBp 0.00

RENE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $2.95 USD -0.07
Geron Corp $2.93 USD -0.10
Neuralstem Inc $1.48 USD +0.02
Ocata Therapeutics Inc $4.38 USD +0.15
StemCells Inc $0.46 USD +0.05
View Industry Companies
 

Industry Analysis

RENE

Industry Average

Valuation RENE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 181.9x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 320.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RENEURON GROUP PLC, please visit www.reneuron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.